Werewolf Therapeutics receives Nasdaq notice for minimum bid price deficiency
#Werewolf Therapeutics #Nasdaq #Minimum bid price #HOWL #Stock deficiency #Compliance #Biopharmaceutical
📌 Key Takeaways
- Nasdaq issued a deficiency notice to Werewolf Therapeutics for failing to maintain a $1.00 minimum bid price.
- The company has until late 2024 (180 days) to regain compliance with the listing rules.
- Compliance requires the stock price to trade at or above $1.00 for ten consecutive business days.
- The company's stock symbol 'HOWL' remains active and trading is currently unaffected.
📖 Full Retelling
Werewolf Therapeutics, Inc., a biopharmaceutical company specializing in cancer immunotherapy, received a formal notification from the Nasdaq Stock Market on May 22, 2024, regarding its failure to maintain the minimum bid price required for continued listing on the Nasdaq Global Market. The deficiency notice was triggered because the company's common stock had closed below the $1.00 per share threshold for 30 consecutive business days. This regulatory intervention serves as a standard enforcement of exchange listing rules designed to ensure that publicly traded companies maintain a basic level of market valuation and investor confidence.
Following the receipt of the notice, the Cambridge-based firm has been granted a grace period of 180 calendar days to regain compliance with the exchange's requirements. To rectify the situation, the closing bid price of Werewolf Therapeutics' common stock must reach at least $1.00 per share for a minimum of ten consecutive business days at any point during this six-month window. If the company fails to meet this target by the deadline, it may be eligible for an additional 180-day extension, provided it meets other listing criteria and notifies the exchange of its intent to cure the deficiency, potentially through a reverse stock split.
The notification does not immediately impact the trading of Werewolf Therapeutics' stock, which continues to be listed under the ticker symbol 'HOWL.' However, the development highlights the ongoing financial pressures facing mid-stage biotech firms in a volatile market environment. Management has indicated that they will monitor the stock price closely and explore various strategic options to address the deficiency while continuing to advance their clinical pipeline of conditionally activated INDUKINE molecules for the treatment of solid tumors.
🐦 Character Reactions (Tweets)
Biotech BuffWerewolf Therapeutics got a 'howl' from Nasdaq. Stock below $1? Time to call in the pack for a reverse stock split! 🐺📉
Market MavenNasdaq says 'show me the money' to Werewolf Therapeutics. Time to howl at the moon and hope for a miracle rally! 🌙💸
Finance FangsWerewolf Therapeutics: From clinical trials to stock price trials. Can they bite back in time? 🦴📊
Biotech BanterNasdaq to Werewolf Therapeutics: 'Your stock is looking a bit under the weather.' Time to howl back with a comeback! 🐺💊
💬 Character Dialogue
1:
The gods of Wall Street have spoken. Another company falls to the curse of the market.
2:
Well, at least they didn't get delisted for being too 'wolfy' 🐺. That would've been embarrassing. 😂
3:
The dark side of the market is strong with this one. The Force of finance is not on their side.
1:
Perhaps they should have focused on their clinical trials instead of chasing the stock price.
2:
Yeah, but hey, at least their stock symbol is 'HOWL' 🐺. That's gotta be worth something, right? 😂
🏷️ Themes
Finance, Biotechnology, Stock Market
📚 Related People & Topics
Nasdaq
American stock exchange
# Nasdaq Stock Market The **Nasdaq Stock Market** (an acronym for *National Association of Securities Dealers Automated Quotations*) is an American stock exchange based in Manhattan, New York City. It distinguishes itself as the first fully electronic stock market in the world and currently ranks a...
🔗 Entity Intersection Graph
Connections for Nasdaq:
- 🌐 SEC filing (5 shared articles)
- 🌐 Stock market (3 shared articles)
- 🏢 Initial public offering (2 shared articles)
- 🌐 Artificial intelligence (2 shared articles)
- 🏢 Corporate governance (2 shared articles)
- 🌐 Environmental technology (1 shared articles)
- 🏢 CECO Environmental (1 shared articles)
- 🌐 Industrial engineering (1 shared articles)
- 👤 Wall Street (1 shared articles)
- 🌐 Amazon (1 shared articles)
- 🏢 Glaucoma (1 shared articles)
- 🏢 Xometry (1 shared articles)
📄 Original Source Content
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry As Claude disrupts stock market, Anthropic researcher warns ’world is in peril’ Gold, silver prices rise amid U.S.-Iran tensions, blowout January payrolls data Dow halts three-day win streak as blowout jobs data curbs rate cut bets Citi pushes back Fed rate cuts to May after blowout January jobs report (South Africa Philippines Nigeria) Werewolf Therapeutics receives Nasdaq notice for minimum bid price deficiency SEC Filings Published 02/06/2026, 07:31 PM Werewolf Therapeutics receives Nasdaq notice for minimum bid price deficiency 0 HOWL -6.49% Werewolf Therapeutics, Inc. (NASDAQ:HOWL) announced it received a deficiency letter from the Nasdaq Stock Market on Wednesday, notifying the company that its common stock had closed below the $1.00 per share minimum bid price requirement for the last 30 consecutive business days. The notice was issued under Nasdaq Listing Rule 5450 1), which sets the minimum bid price standard for continued listing on the Nasdaq Global Select Market. According to InvestingPro data, HOWL’s stock is currently trading at $0.61, having fallen 48.12% over the past six months, with a modest market capitalization of just $30.58 million. InvestingPro analysis suggests the stock is slightly undervalued at current levels. According to a statement in the company’s SEC filing, the notice does not immediately affect the listing or trading of Werewolf Therapeutics’ common stock. The company now has an initial period of 180 calendar days, expiring on August 3, 2026, to regain compliance with the minimum bid price requirement. To do so, the closing bid price of its common stock must meet or exceed $1.00 per share for at least 10 consecutive business days during this period. If Werewolf Therapeutics does not regain compliance within the initial 180 days, it may qualify for an additional 180-day compliance period by transferring its listing to the Nasdaq Capital Market, provided it meets the other appl...